A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Indian and Alaska Native Cancer Patients Living in Rural California
Part of paid clinical trials in Bishop, California.
- Sponsor
- University of Southern California
- Study ID
- NCT07332312
- Status
- Recruiting
Conditions
- Hematopoietic and Lymphatic System Neoplasm
- Malignant Solid Neoplasm
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Accepted
Interventions
- Discussion — OTHERServe on CAB
- Discussion — OTHERComplete focus group
- Educational Intervention — OTHERReceive opioid misuse education and care coordination
- Electronic Health Record Review — OTHERAncillary studies
- Interview — OTHERComplete KII
- Interview — OTHERAncillary studies
- Patient Navigation — BEHAVIORALEngage with CFPN program navigator
- Survey Administration — OTHERAncillary studies
- Tailored Intervention — PROCEDUREReceive treatment plan
Study Details
This clinical trial develops and tests whether a culturally informed patient navigation program, Community-Focused Patient Navigation (CFPN), works to reduce delays between diagnosis and treatment in American Indian and Alaska Native (AIAN) cancer patients living in rural California. AIAN communities face some of the most severe cancer disparities in the United States, including higher death rates, later-stage diagnoses, and limited access to timely, culturally responsive care. This may be due to barriers such as rural isolation, divided referral systems, or a lack of trust in mainstream healthcare systems. Patient navigation is a care delivery model designed to guide a patient through the healthcare system and address the barriers that prevent patients from accessing timely and effective care. The CFPN program is culturally tailored and designed with AIAN communities in mind. The program provides the patient with a treatment plan based on the patient's unique needs, goals, and barriers. This may be an effective way to reduce delays between diagnosis and treatment in AIAN cancer patients living in rural California.
Key Dates
- Start date
- Apr 17, 2026
- Status verified
- May 2026
- Primary completion
- Nov 13, 2027
- Completion
- Nov 13, 2028
Study Design
- Enrollment
- 71 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Other: Objective 1 group I (CAB)Participants serve on a CAB to guide the co-design process of the CFPN program on study.
- Other: Objective 1 group II (focus group)Participants complete a focus group over 1-2 hours in support of the co-design process of the CFPN program on study.
- Other: Objective 1 group III (KII)Participants complete a KII over 30 minutes in support of the co-design process of the CFPN program on study.
- Experimental: Objective 2 (CFPN program)Patients engage with the CFPN program navigator as needed and receive a treatment plan based on the patient's needs, goals, and barriers on study. Patients also receive opioid misuse education and care coordination on study.
Primary Outcome Measure
Focus group themes and emerging codes [ Time Frame: Through study completion, up to 2 years ]
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Toiyabe Indian Health Project | Bishop | California | 93514 | Tina Cassar (PRINCIPAL_INVESTIGATOR) |
| USC / Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Claradina Soto (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Bishop, CA
Related Studies
- Project: Every Child for Younger Patients With CancerRecruiting · Children's Oncology Group · Birmingham, Alabama
- Collection and Storage of Tissue and Blood Samples From Patients With CancerRecruiting · National Cancer Institute LAO · Birmingham, Alabama
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid TumorsRecruiting · SWOG Cancer Research Network · Anchorage, Alaska